Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04172441 · ClinicalTrials.gov registry record · Phase 2
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
A Phase 2 study of Congenital Hyperinsulinism, sponsored by Zealand Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 6
- Study locations
NCT04172441 is a Phase 2 study of Congenital Hyperinsulinism that has completed, run by Zealand Pharma. The registered enrollment target is 12 participants, below the 77-participant average among 7 other Congenital Hyperinsulinism trials with a reported enrollment target (84% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT04172441, a Phase 2 study of Congenital Hyperinsulinism, has completed, sponsored by Zealand Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objective of the trial is to evaluate the efficacy of dasiglucagon in reducing glucose requirements in children with persistent congenital hyperinsulinism (CHI) requiring continuous intravenous (IV) glucose administration to prevent/manage hypoglycemia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG dasiglucagon
Study Locations (6)
Other
- University Children's Hospital - Düsseldorf
- University Hospital, Magdeburg - Magdeburg
- Hadassah Medical Center - Jerusalem
- Manchester University NHS Foundation Trust - Manchester
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- Cook Children's Medical Center - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-06-19 |
| Est. Completion | 2022-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04172441
The ClinicalTrials.gov registry entry for NCT04172441 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 77-participant average among 7 other Congenital Hyperinsulinism trials with a reported enrollment target (84% lower). The listed sponsor is Zealand Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congenital Hyperinsulinism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04172441 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Other, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT04172441 about?
NCT04172441 is a clinical study titled "Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism". The objective of the trial is to evaluate the efficacy of dasiglucagon in reducing glucose requirements in children with persistent congenital hyperinsulinism (CHI) requiring continuous intravenous (IV) glucose administration to prevent/manage hypoglycemia.
What is the current status of trial NCT04172441?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2020-06-19. Estimated completion is 2022-03-07.
What conditions does trial NCT04172441 study?
This clinical trial studies the following conditions: Congenital Hyperinsulinism.
What interventions are being tested in trial NCT04172441?
The interventions under investigation include: Placebo (DRUG), dasiglucagon (DRUG).
Who is sponsoring clinical trial NCT04172441?
This trial is sponsored by Zealand Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04172441 being conducted?
This trial has 6 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Hyperinsulinism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
RECRUITING · Phase 2
-
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
RECRUITING · Phase 2
-
Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
COMPLETED · Phase 2
-
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
RECRUITING · Phase 1
-
RZ358 Treatment for Congenital Hyperinsulinism
ACTIVE NOT RECRUITING · Phase 3
-
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.